Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Bintrafusp Alfa Shows Efficacy but Does Not Meet Predetermined Threshold in BTC Trial
March 18th 2021Bintrafusp alfa monotherapy demonstrated efficacy, durability, and a manageable safety profile in patients with locally advanced or metastatic biliary tract cancer who have progressed or are intolerant to first-line platinum-based chemotherapy in a phase 2 study, but failed to meet the pre-determined threshold for a regulatory filing.
Read More
ASCO Releases Yearly Report on Progress in Cancer Research, Racial Equity Named a Critical Issue
March 17th 2021Despite the coronavirus disease 2019 pandemic, major progress in cancer research has been made in the past year in the areas of molecular profiling, biomarker-driven treatment approaches, targeted therapies brought into earlier stages of disease, treatment combinations with limited toxicities, and treatments that extend survival for hard-to-treat cancers.
Read More
FDA Receives New Drug Application for Ivosidenib in IDH1+ Cholangiocarcinoma
March 1st 2021A New Drug Application was submitted to the FDA for ivosidenib tablets as a potential treatment option for patients with previously treated IDH1-mutated cholangiocarcinoma. The company is requesting Priority Review be granted to the application.
Read More
Unique Findings With Binimetinib Plus Imatinib in Advanced GIST
February 19th 2021Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib plus imatinib as treatment of patients with untreated advanced gastrointestinal stromal tumors.
Watch
Derzantinib Induces Responses in Patients With Advanced Intrahepatic Cholangiocarcinoma
February 12th 2021In the phase 2 FIDES-01 clinical trial, treatment with the FGFR inhibitor, derazantinib, led to an objective response rate of 24% in patients with FGFR2 gene fusion-positive advanced intrahepatic cholangiocarcinoma.
Read More
NBTXR3 Injected in First Patient With Esophageal Cancer in Phase 1 Study
February 2nd 2021In the phase 1 clinical trial of NBTXR3 with chemotherapy and radiation therapy as treatment of patients with esophageal cancer, the first patient has been dosed with the investigational tumor-agnostic radioenhancer.
Read More
FDA Grants Priority Review to 1L Nivolumab Combination in Gastric/GEJ/Esophageal Cancers
January 20th 2021The FDA has granted a Priority Review to the combination of nivolumab with fluoropyrimidine- and platinum-containing chemotherapy, which is a potential treatment option for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Read More
FDA Grants Priority Review to Adjuvant Nivolumab for Resected Esophageal/GEJ Cancer
January 20th 2021The FDA accepted a supplemental Biologics License Application for nivolumab as adjuvant treatment of patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiation therapy and granted it Priority Review.
Read More
Trastuzumab Deruxtecan Brings HER2 Targeted Therapy to 3L HER2+ Advanced Gastric/GEJ Cancers
January 18th 2021In an interview with Targeted Oncology, Yelena Y. Janjigian, MD, provided important highlights from the DESTINY-Gastric01 trial and explained the overall impact of the FDA approval of trastuzumab deruxtecan for oncologists treating patients with HER2-positive advanced gastric cancer or GEJ cancers.
Read More
Ivosidenib Produces Encouraging OS Data in Previously Treated Cholangiocarcinoma
January 18th 2021Andrew X. Zhu, MD, PhD, discusses the final results from the phase 3 ClarIDHy study of ivosidenib versus placebo as treatment of patients with previously treated cholangiocarcinoma and an IDH1 mutation.
Watch
Second-Line Pembrolizumab Shows Continued OS and PFS Improvement in Advanced HCC
January 18th 2021In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.
Read More
Activity, Tolerability Observed for Axitinib in Pancreatic NETs, but PFS Misses Mark
January 17th 2021The combination of axitinib and octreotide LAR demonstrated activity and a tolerable safety profile in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors in a phase 2/3 study.
Read More